JW Pharmaceuticals

What JW Pharmaceuticals does

JW Pharmaceuticals (JW중외제약, legal name JW Pharmaceutical Corporation) is a Seoul-headquartered, publicly traded South Korean pharmaceutical company founded in 1945 (originally as Choongwae Pharmaceutical) and operating as a subsidiary of JW Holdings, which holds ~42% of ordinary shares. The company develops, manufactures, and commercializes prescription pharmaceuticals and consumer health products, with a particular focus on parenteral nutrition, cardiovascular/metabolic disease, hematology, oncology, immunology, rare diseases, and regenerative medicine. Its core commercial portfolio includes Winuf and Combiflex (3-chamber total parenteral nutrition products, the latter containing omega-3-rich fish oil), LIVALO (pitavastatin for hyperlipidemia with expanding combination approvals), Hemlibra (emicizumab for hemophilia A), Mobilia (plerixafor for hematopoietic stem-cell mobilization), Neutrogin (G-CSF), Tavalisse (fostamatinib for thrombocytopenia), Actemra, and consumer brands such as Hi-mom Band, Frenzeye drops, and the newly launched Ganetoktok hangover relief stick.

The technology base spans three integrated R&D platforms: the J-Wave AI drug discovery platform coupled with robot-based synthesis automation, the JWELRY peptide-mimetic compound library (approximately 25,000 compounds) used for high-throughput screening, and the CLOVER omics database of cancer cell lines, tissues, and genetic information. Specialty platforms target Wnt and STAT3 signaling (oncology and regenerative medicine), URAT1 inhibition (Epaminurad for gout/hyperuricemia), GFRA1 agonism (JW0061 for alopecia), and the SMEDDS solubilization technology for poorly soluble drugs. Research is conducted across the Gwacheon Drug Discovery Center, C&C Research Laboratories in Suwon, and JW Theriac in Boston, with a 31-compound pipeline across nine therapeutic areas and R&D spend above 14% of revenue.

Commercially, JW generates revenue from three streams: product sales of branded prescription drugs and consumer health products (FY2024 consolidated revenue of 719,376 million KRW, approximately $540M USD) sold via hospital, pharmacy, and online-pharmacy channels in Korea; international exports to 50+ countries through long-standing channel partners including Baxter, Abbott, Chugai, Kyowa Kirin, Sandoz, and Vifor (some relationships dating to 1971); and licensing/royalty income from both inbound deals (e.g., the April 2026 Gan & Lee bofanglutide agreement worth up to $81.1M covering GLP-1 indications in Korea) and outbound deals (e.g., JW1601 to LEO Pharma, URC102 to Simcere). The company operates five domestic manufacturing plants (Gwacheon, Pyeongtaek, Cheongju, Anseong, Jincheon) plus the overseas JW Euvipharm facility, and supplements R&D with Korean government grants, including a 2026 2.2 billion KRW award for AI-driven structure-based drug development.

Name

JW Pharmaceuticals

Legal name

JW Pharmaceutical Corporations

Website

https://jw-pharma.co.kr

Company type

Public

Founded year

1941

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

JW Pharmaceuticals is a South Korean pharmaceutical company that develops, manufactures, and commercializes prescription drugs (parenteral nutrition, cardiovascular, oncology, hematology) and consumer health products, supported by AI-driven drug discovery, and sells domestically and in 50+ countries via long-standing global distribution partners.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Prescription pharmaceuticals
• Parenteral nutrition solutions
• Oncology therapeutics
• Rare disease treatments
• Consumer health products

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sales of prescription pharmaceuticals including cardiovascular/metabolic drugs (Livalo franchise), oncology products (Mobilia), hematology (Hemlibra), infusion solutions (Winuf, Combiflex), and consumer healthcare products
2. Licensing and Royalty Revenue: Inbound licensing deals for commercialization rights (e.g., $5M upfront + $76.1M milestones from Gan & Lee for bofanglutide) and outbound licensing of proprietary compounds (e.g., license-out of URC102 to Simcere, JW1601 to LEO Pharma)
3. Government R&D Grants: Government funding support for AI drug development projects including 2.2 billion won over three years from Ministry of Health and Welfare for structure-based AI drug development

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

JW Pharmaceuticals is a South Korean pharmaceutical company that researches, develops, manufactures, and commercializes prescription drugs and consumer healthcare products. Its core prescription portfolio spans parenteral nutrition solutions (WINUF, COMBIFLEX), lipid management (LIVALO), hemophilia A therapy (HEMLIBRA), oncology (MOBILIA, Neutrogin), and immunology (ACTEMRA), supported by a 31-compound R&D pipeline and the J-Wave AI drug discovery platform. Consumer health offerings include Hi-mom Band wound care, Frenzeye artificial tears, and Ganetoktok hangover relief.

Product overview

JW Pharmaceutical operates as a South Korean pharmaceutical company with a diversified portfolio spanning prescription drugs, consumer health products, and a clinical pipeline. Core prescription products include WINUF (omega-3 rich parenteral nutrition), COMBIFLEX (3-chamber TPN systems), LIVALO (pitavastatin for cholesterol), HEMLIBRA (hemophilia A treatment), and Neutrogin (G-CSF for neutropenia). Consumer health offerings include Hi-mom Band hydrocolloid wound care products, Frenzeye artificial tears, and the newly launched Ganetoktok hangover relief stick. The R&D pipeline features 31 compounds across oncology, immunology, cardiovascular/metabolic diseases, regenerative medicine, rare diseases, and ophthalmology, including DDC-02 for rare neurodevelopmental disorders, JW0061 for alopecia, JW2286 as a STAT3 inhibitor, and Epaminurad for gout. The company also operates an AI-powered drug discovery platform J-Wave for novel compound development.

Differentiator

Problem solved

Functional benefit

Brands

• Hi-mom Band: Wound care products including hydrocolloid band-aids, burn sprays, and foam dressings
• Frenzeye Drop
• Ganetoktok

Products and services

• WINUF Injection 3-chamber bag parenteral nutrition product containing omega-3 rich fish oil, glucose, amino acids, and electrolytes for patients unable to receive oral or enteral nutrition. Contains highest fish oil content in Korea with optimized ω-6:ω-3 ratio of 2.1:1 for anti-inflammatory and immune function. Distributed in the USA market through Baxter.
• COMBIFLEX Lipid Central/Peri Injection Total parenteral nutrition (TPN) product with 3-chamber bag system containing amino acids, glucose, and lipids. Available in central and peripheral formulations for nutritional support in patients unable to receive oral nutrition.
• LIVALO Tablet (Pitavastatin) HMG-CoA reductase inhibitor (statin) for primary hypercholesterolemia and dyslipidemia. Reduces LDL-C and increases HDL-C, with proven efficacy in preventing diabetes onset in J-PRECICT clinical trials. Minimizes CYP450 drug interaction risks.
• HEMLIBRA (Emicizumab) Bispecific monoclonal antibody treatment for routine prophylaxis to reduce or prevent bleeding episodes in hemophilia A patients, with or without factor VIII inhibitors. Non-factor therapy administered subcutaneously with flexible dosing up to once every 4 weeks.
• Neutrogin Injection (Filgrastim/Lenograstim) G-CSF (granulocyte colony-stimulating factor) drug for neutropenia treatment in chemotherapy patients, MDS, aplastic anemia, and for hematopoietic stem cell mobilization. Enhanced safety and efficacy with glycan modification compared to competing products.
• ACTEMRA (Tocilizumab) Immunological disease treatment for rheumatoid arthritis and other inflammatory conditions (IL-6 receptor antagonist).
• MOBILIA (Plerixafor) CXCR4 antagonist for mobilization of hematopoietic stem cells into peripheral blood for autologous transplantation in non-Hodgkin lymphoma and multiple myeloma patients.
• TAVALISSE (Fostamatinib) Spleen Tyrosine Kinase (SYK) inhibitor for treatment of thrombocytopenia. Administered as 100mg oral tablet twice daily.
• DDC-02 Orally administered low-molecule drug candidate for rare neurodevelopmental disorders including Pitt-Hopkins syndrome, Fragile X syndrome, and Rett syndrome. First clinical indication planned as Pitt-Hopkins syndrome with global multi-country trial entry targeted for 2028.
• JW0061 GFRA1 agonist for alopecia treatment. Phase 1 clinical trial stage. U.S. patent registered protecting novel chemical structure through May 2039. Topical formulation targets hair follicle stem cells via GFRA1 receptor for androgenetic alopecia and alopecia areata.
• JW2286 STAT3 inhibitor for oncology applications. First-in-class mechanism. Currently in Phase 1 clinical trials.
• Epaminurad (URC102) URAT1 (urate anion exchanger 1) inhibitor for gout treatment. Best-in-class urate-lowering therapy developed in partnership with Simcere Pharmaceutical. Phase 3 clinical trial completed patient dosing.
• Bofanglutide Injection Bi-weekly GLP-1 receptor agonist for obesity, type 2 diabetes, obstructive sleep apnea, and MASH. Licensed from Gan & Lee Pharmaceuticals for development and commercialization in South Korea.
• Ganetoktok Hangover Relief Stick Grape-flavored jelly stick hangover relief product containing 2,000mg of barley sprout extract concentrate per serving. MFDS-certified functional food with hangover relief efficacy claims, distributed through Korean pharmacy channels.
• Hi-mom Band Hydrocolloid wound care band-aids including premium, cut-and-use, spot, and combination variants. Includes burn spray products for wound protection and moisture management.
• Frenzeye Drops Artificial tear eye drops containing glucose and menthol for temporary relief of dry eye symptoms. Available for all lens types with selectable cooling sensation levels.

Quantifiable outcome

• 684만 명의 환자들에게 퇴장방지의약품 지원 (supplied life-saving fluids to 6.84 million patients)
• +3 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Gan & Lee PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 9 April 2026Exclusive licensing agreement where JW Pharmaceutical secured domestic rights to bofanglutide, a bi-weekly GLP-1 receptor agonist, for development and commercialization in South Korea. Deal includes $5 million upfront payment and up to $76.1 million in milestone payments tied to regulatory approvals across four indications (type 2 diabetes, obesity, obstructive sleep apnea, MASH), plus tiered royalties on net sales with total potential value of $81.1 million.
• China Medical System Holdings Ltd (CMS)minorOEM/ Whitelabel/ Licensing Partner · 1 December 2024Market context: Atom Therapeutics entered exclusive commercialization agreement with CMS to commercialize lingdolinurad (ABP-671) for chronic gout and hyperuricemia across mainland China, Hong Kong, and Macao, showing competitive landscape in gout treatments.
• Theraject Asia Co., Ltd.minorStrategic or Co-development Partner · 1 October 2023Partnership to develop microneedle-based hair loss treatments using proprietary transdermal delivery technology, targeting the growing microneedle drug delivery systems market projected to reach $13.16 billion by 2030.
• Simcere Pharmaceutical Group (China)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2019License-out agreement for gout treatment URC102 (Epaminurad), a novel urate-lowering therapy demonstrating high safety and reduced uric acid levels. JW exported 80 billion won worth of technology to Simcere for this uric acid reduction treatment.
• LEO Pharma (Denmark) - Skin Disease PartnershipminorStrategic or Co-development Partner · 1 May 2019Open innovation partnership with Leoparm, a global leader in skin disease, established during 60th anniversary of Korean-Denmark diplomatic relations.
• LEO Pharma (Denmark)coreOEM/ Whitelabel/ Licensing Partner · 1 August 2018License-out agreement for atopic dermatitis drug candidate JW1601 valued at 450 billion won. Recognized as 'Open Innovation Case' at 60th anniversary of Korea-Denmark diplomatic relations and received Korea Patent Technology King Sejong Grand Prize Award.
• A*STAR Singapore (Agency for Science, Technology and Research)minorStrategic or Co-development Partner · 1 July 2018Collaboration research agreement for new global innovative drugs in immunological disease and anticancer drugs, working with four research institutes under A*STAR and National Skin Centre. Three-year collaboration with steering committee meetings held twice yearly.
• C&C Drug Research Institute (C&C Research Laboratories)coreStrategic or Co-development PartnerSubsidiary collaboration for AI-driven drug development, combining C&C's structure-based drug discovery capabilities with JW's J-Wave AI platform and robot-based synthesis automation for the Ministry of Health and Welfare's 'Structure-Based AI Drug Development Support' project with 2.2 billion won government funding over three years.
• Chinese AI-Biotech Firms (Sineron Bio, CrystalPi)minorStrategic or Co-development PartnerMarket context indicating South Korean pharma companies including JW Pharmaceutical are actively pursuing license-in and co-development deals with Chinese companies for GLP-1 candidates and antibody-drug conjugates as part of Asia-Pacific partnership strategies.
• BaxtercoreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for distribution of Winuf (3-Chamber I.V. solution) in USA market.
• AbbottcoreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for pharmaceutical product distribution.
• Shire (Takeda)coreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for pharmaceutical product distribution.
• Chugai PharmaceuticalcoreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for pharmaceutical product distribution and potential co-development activities.
• Kyowa KirincoreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for pharmaceutical product distribution in Asia-Pacific markets.
• Sandoz (Novartis)coreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for generic pharmaceutical distribution.
• Vifor PharmacoreChannel Partner/ Reseller/ DistributorLong-standing partnership since 1971 for pharmaceutical product distribution including iron deficiency treatments.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Boryung Pharmaceutical: Korean pharma with prescription and OTC portfolio across cardiovascular and gastrointestinal therapeutic areas; competes in similar Korean market segments and runs comparable consumer health brand development initiatives.
• Daewoong Pharmaceutical: Korean pharmaceutical manufacturer with a diversified prescription and consumer health portfolio across similar therapeutic areas (gastroenterology, endocrinology, dermatology); comparable export footprint to multiple Asian and emerging markets through licensing.
• Dong-A ST: Korean specialty pharma with comparable branded prescription portfolio (gastroenterology, neurology, oncology) and consumer health presence; competes for hospital prescribing share and operates a similar AI/digital R&D transformation initiative.
• Hanmi Pharmaceutical: Korean specialty pharmaceutical company with a comparable R&D-intensive model focused on innovative drugs in oncology, metabolic disease, and immunology; competes directly with JW for Korean hospital formulary placement and has similar international licensing partnerships.
• Chong Kun Dang (CKD) Pharmaceutical: Mid-tier Korean pharmaceutical company with comparable revenue scale, diversified prescription portfolio across cardiovascular, antibiotics, and consumer health; direct overlap in Korean hospital and pharmacy channels.
• Green Cross Holdings (GC Pharma): Korean pharmaceutical and biologics company with overlapping products in plasma-derived therapies, vaccines, and prescription drugs; similar historical export footprint and hospital-channel commercialization approach in Korean market.

Regional players

• Huons Global: Korean pharmaceutical company with comparable portfolio across injectables, dermo-cosmetics, and consumer health; similar revenue tier and overlapping presence in Korean pharmacy channels with extension to Southeast Asian markets.

Broad incumbents

• Celltrion: Larger Korean biopharmaceutical leader focused on biosimilars and novel biologics; broader scale and stronger biologics manufacturing capabilities but similar international licensing strategy and Korean regulatory expertise.
• Yuhan Corporation: Larger established Korean pharmaceutical incumbent with broader therapeutic portfolio, stronger consumer health business, and significant licensing deals (e.g., lazertinib with Janssen); represents a more diversified scale competitor in the same Korean pharma landscape.

Emerging players

• Hanall Biopharma: Smaller Korean specialty pharma with focused pipeline in ophthalmology, immunology, and rare diseases; comparable niche strategy targeting specialty therapeutic areas with selective licensing-out to global partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jw-pharmaceutical-corporation

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Pharmaceuticals